Maxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDPResearch Report). The company’s shares closed yesterday at $1.62.

According to TipRanks, McCarthy is an analyst with an average return of -33.9% and a 15.65% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, BioNano Genomics, and Lineage Therap.

Indaptus Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing an 825.93% upside. In a report released on March 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $4.25 and a one-year low of $1.25. Currently, Indaptus Therapeutics has an average volume of 9,598.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.

Read More on INDP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More